EHA 2024 | A subgroup analysis of MajesTEC-1: teclistamab in multiple myeloma with high-risk features
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses a subgroup analysis from the MajesTEC-1 trial (NCT04557098), focusing on the efficacy and safety of teclistamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) with high-risk features. Teclistamab shows activity across subgroups, though response rates are slightly lower in those with extramedullary disease and multiple high-risk abnormalities. Combining teclistamab with other agents, as seen in the RedirecTT-1 trial (NCT04586426) with talquetamab, could improve efficacy in this population. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
